Business
AEON Biopharma is advancing ABP-450, a proprietary botulinum toxin complex, as a biosimilar to Botox for debilitating medical conditions in the United States.
AEON is pivoting ABP-450 toward a Botox biosimilar path with no product revenue, $3.0M cash, and going-concern risk.
The read at a glance✓ Audited against SEC data
- Business mix — ABP-450 botulinum toxin candidateNote
- Revenue — No product revenueNote
- Profitability — Net loss was $39.2MWatch
- Cash burn — Free cash flow was -$17.3MWatch
- Balance sheet — Equity deficit widened to $55.0MWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Going-concern warningWatch
Leadership changes
From AEON Biopharma, Inc.'s own filings, the day they're filed.
- John Bencich · Chief Financial Officer · appointmenteff. 2026-03-09
- Robert Bancroft · Principal Executive Officer · appointmenteff. 2025-04-29
- Jost Fisher · Chief Executive Officer · departureeff. 2025-04-29
Latest filings
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-07-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AEON Biopharma, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.